Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTXZ), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. reports developments from its clinical-stage biotechnology business, which focuses on cancer immunotherapies for metastatic breast cancer and other oncology indications. Recurring updates center on Bria-IMT, its targeted cell-based immunotherapy regimen, Bria-OTS, its personalized off-the-shelf immunotherapy platform, and biomarker, survival, safety and clinical-response data from breast cancer studies.
Company news also covers scientific conference presentations, FDA Fast Track status for the Bria-IMT regimen, and research activity at BriaPro Therapeutics, including work on anti-cancer small-molecule kinase inhibitors through drug-discovery collaborations.
BriaCell Therapeutics (NASDAQ: BCTX) reported sustained complete resolution of lung metastasis in the first patient treated with Bria-OTS, their personalized off-the-shelf immunotherapy for metastatic breast cancer. The 78-year-old patient with hormone receptor-positive, HER2-negative metastatic breast cancer showed 100% resolution of lung metastasis, maintained at 2, 4, and 6 months after treatment.
The patient, who had multiple prior treatment failures, has received 12 cycles of Bria-OTS monotherapy with no treatment-limiting toxicities. This milestone was achieved at the lowest dose level, demonstrating strong single-agent activity in a challenging patient population.
BriaCell Therapeutics (NASDAQ: BCTX) has reported impressive survival data from its Phase 2 clinical study of Bria-IMT in metastatic breast cancer patients. The study showed that 52% of the most recent 25-patient cohort survived beyond one year, surpassing current standard of care expectations. Notably, 11 patients remain alive, with two remarkable cases reaching 38.3 and 30.3 months of survival.
The study included heavily pre-treated patients who had previously failed multiple therapies, including checkpoint inhibitors and antibody-drug conjugates. The median number of prior treatments was 6, and importantly, no treatment discontinuations related to Bria-IMT have been reported, suggesting a well-tolerated profile.
BriaCell Therapeutics (NASDAQ: BCTX) has expanded its pivotal Phase 3 clinical trial for advanced metastatic breast cancer treatment by adding two major cancer centers: Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, contributing 30 additional satellite locations. The study now encompasses 58 active clinical sites across 15 states.
The trial evaluates BriaCell's lead candidate Bria-IMT™ plus immune checkpoint inhibitor versus physician's choice. Patient enrollment is expected to complete by late 2025 or early 2026, with potential top-line data release in H1-2026. The study's primary endpoint will analyze overall survival after 144 patient events, with positive results potentially leading to full approval and marketing authorization.
BriaCell Therapeutics (NASDAQ: BCTX) has received a positive safety review recommendation from the independent Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer. This marks the third consecutive positive recommendation from the DSMB, which found no safety concerns and recommended the study continue without modifications.
The study is being conducted under FDA Fast Track Designation, highlighting the significant unmet medical need in metastatic breast cancer patients. The DSMB reviews occur quarterly as per study protocol, and this latest recommendation further validates the favorable safety profile of BriaCell's immunotherapy treatment.